Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

This study has been terminated.
(An arm closed due to lack of efficacy)
Janssen-Cilag International NV
Information provided by:
Lymphoma Study Association Identifier:
First received: August 26, 2005
Last updated: October 22, 2010
Last verified: October 2010
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2010
  Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)